Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
IVXA-12 by Icosavax for Human Metapneumovirus Infections: Likelihood of Approval
IVXA-12 is under clinical development by Icosavax and currently in Phase II for Human Metapneumovirus Infections. According to GlobalData, Phase...
IVXA-12 by Icosavax for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
IVXA-12 is under clinical development by Icosavax and currently in Phase II for Respiratory Syncytial Virus (RSV) Infections. According to...
Risk adjusted net present value: What is the current valuation of AstraZeneca's IVXA-12?
IVXA-12 is a subunit vaccine commercialized by AstraZeneca, with a leading Phase II program in Respiratory Syncytial Virus (RSV) Infections;Human...
IVXA-12 by Icosavax for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
IVXA-12 is under clinical development by Icosavax and currently in Phase II for Respiratory Syncytial Virus (RSV) Infections. According to...
IVXA-12 by Icosavax for Human Metapneumovirus Infections: Likelihood of Approval
IVXA-12 is under clinical development by Icosavax and currently in Phase II for Human Metapneumovirus Infections. According to GlobalData, Phase...